Clinical characteristics of patients with different types of additional chromosomal abnormalities
| . | 3q26.2, n = 25 . | −7/7q−, n = 13 . | i(17q), n = 22 . | +8, n = 45 . | +Ph, n = 42 . | Other single, n = 186 . | High-risk complex, n = 74 . | Other complex, n = 163 . | No ACA, n = 1756 . |
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Male | 20 | 10 | 14 | 27 | 29 | 108 | 46 | 99 | 969 |
| Female | 5 | 3 | 8 | 18 | 13 | 78 | 28 | 64 | 787 |
| Age at Dx, y | |||||||||
| Median | 52 | 57 | 44 | 46 | 48 | 48 | 52 | 48 | 49 |
| Range | 21-76 | 26-70 | 22-73 | 21-75 | 22-86 | 18-81 | 20-78 | 19-88 | 18-87 |
| Interval 1, mo* | |||||||||
| Median | 15.2 | 8.3 | 33.3 | 12.9 | 33.6 | 5.8 | 14.0 | 14.6 | N/A |
| Range | 0-122 | 0-111 | 0-112 | 0-100 | 0-182 | 0-159 | 0-143 | 0-203 | N/A |
| Interval 2, mo† | |||||||||
| Median | 2.8 | 0 | 32.6 | NR | NR | NR | 0 | 19.2 | N/A |
| BP phenotype | |||||||||
| Myeloid | 21 | 4 | 14 | 7 | 7 | 47 | 46 | 66 | 64 |
| Lymphoid | 0 | 6 | 2 | 5 | 3 | 23 | 14 | 24 | 52 |
| Mixed phenotype | 0 | 1 | 0 | 0 | 1 | 5 | 0 | 3 | 3 |
| No BP | 4 | 2 | 6 | 33 | 31 | 111 | 14 | 70 | 1637 |
| ACA emergence | |||||||||
| Before BP | 12 | 2 | 9 | 5 | 7 | 21 | 15 | 24 | N/A |
| At BP | 6 | 6 | 2 | 4 | 2 | 36 | 32 | 47 | N/A |
| After BP | 3 | 3 | 5 | 3 | 2 | 18 | 13 | 22 | N/A |
| Response‡ | |||||||||
| CCyR or deeper | 5 | 2 | 3 | 18 | 19 | 82 | 12 | 43 | 1249 |
| MMR or deeper | 6 | 1 | 3 | 18 | 13 | 62 | 9 | 37 | 1112 |
| Status at last F/U | |||||||||
| Alive | 3 | 2 | 3 | 24 | 30 | 95 | 19 | 60 | 1434 |
| Dead | 22 | 11 | 19 | 21 | 12 | 91 | 55 | 103 | 322 |
| Allo-HSCT | 12 | 3 | 3 | 8 | 6 | 33 | 26 | 35 | 128 |
| . | 3q26.2, n = 25 . | −7/7q−, n = 13 . | i(17q), n = 22 . | +8, n = 45 . | +Ph, n = 42 . | Other single, n = 186 . | High-risk complex, n = 74 . | Other complex, n = 163 . | No ACA, n = 1756 . |
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Male | 20 | 10 | 14 | 27 | 29 | 108 | 46 | 99 | 969 |
| Female | 5 | 3 | 8 | 18 | 13 | 78 | 28 | 64 | 787 |
| Age at Dx, y | |||||||||
| Median | 52 | 57 | 44 | 46 | 48 | 48 | 52 | 48 | 49 |
| Range | 21-76 | 26-70 | 22-73 | 21-75 | 22-86 | 18-81 | 20-78 | 19-88 | 18-87 |
| Interval 1, mo* | |||||||||
| Median | 15.2 | 8.3 | 33.3 | 12.9 | 33.6 | 5.8 | 14.0 | 14.6 | N/A |
| Range | 0-122 | 0-111 | 0-112 | 0-100 | 0-182 | 0-159 | 0-143 | 0-203 | N/A |
| Interval 2, mo† | |||||||||
| Median | 2.8 | 0 | 32.6 | NR | NR | NR | 0 | 19.2 | N/A |
| BP phenotype | |||||||||
| Myeloid | 21 | 4 | 14 | 7 | 7 | 47 | 46 | 66 | 64 |
| Lymphoid | 0 | 6 | 2 | 5 | 3 | 23 | 14 | 24 | 52 |
| Mixed phenotype | 0 | 1 | 0 | 0 | 1 | 5 | 0 | 3 | 3 |
| No BP | 4 | 2 | 6 | 33 | 31 | 111 | 14 | 70 | 1637 |
| ACA emergence | |||||||||
| Before BP | 12 | 2 | 9 | 5 | 7 | 21 | 15 | 24 | N/A |
| At BP | 6 | 6 | 2 | 4 | 2 | 36 | 32 | 47 | N/A |
| After BP | 3 | 3 | 5 | 3 | 2 | 18 | 13 | 22 | N/A |
| Response‡ | |||||||||
| CCyR or deeper | 5 | 2 | 3 | 18 | 19 | 82 | 12 | 43 | 1249 |
| MMR or deeper | 6 | 1 | 3 | 18 | 13 | 62 | 9 | 37 | 1112 |
| Status at last F/U | |||||||||
| Alive | 3 | 2 | 3 | 24 | 30 | 95 | 19 | 60 | 1434 |
| Dead | 22 | 11 | 19 | 21 | 12 | 91 | 55 | 103 | 322 |
| Allo-HSCT | 12 | 3 | 3 | 8 | 6 | 33 | 26 | 35 | 128 |
CCyR, complete cytogenetic response; Dx, diagnosis; F/U, follow-up; MMR, major molecular response; N/A, not applicable; NR, not reached.
Interval 1: time interval from initial diagnosis of CML to the emergence of ACAs.
Interval 2: time interval from emergence of ACAs to blastic transformation.
Response after emergence of ACAs but before blastic transformation. All ACAs, regardless of the emerging time, were included.